安立生坦治疗肺动脉高压的临床研究

Treatment of pulmonary arterial hypertension by Ambrisentan

目的：观察安立生坦治疗肺动脉高压的临床疗效及安全性。方法：选择我科2012-05-10收治的14名肺动脉高压患者,其中男6例,女8例,平均年龄（52±18）岁,观察口服安立生坦治疗3个月前后NT-proBNP、肝功能、6 min步行距离（6MWD）、右心导管检查各项指标的变化。结果：经安立生坦治疗后,患者的活动耐力得到了明显提升,NT-proBNP、6MWD、平均肺动脉压力（mPAP）、肺血管阻力（PVR）、心排量（CO）较前明显改善（P〈0.05）;而治疗前后患者肝功能（AST、ALT、TBIL）没有明显差异（P〉0.05）。结论：安立生坦可以降低患者mPAP及PVR,改善心功能,提高患者6 min步行实验距离,且安全性较高。

Objective： To investigate the efficiency and safeness of Ambrisentan in the treatment of pulmonary arterial hypertension（PAH）. Methods： A total of 14 PAH patients with 8 females and 6 males aged （52_＋18） years were consecutively recruited from May 2012 to October 2012. Three months beforeand after oral administration of Ambrisentan, NT--proBNP, hepatic function and 6 minutes walk test （6MWD） were examined while right heart catheterization was conducted. Results. After the treatment of Ambrisentan, exercise tolerance, NT-proBNP, 6MWD, mean pulmonary arterial pressure （mPAP）, pulmonary vascular resistance（PVR） and cardiac output（CO） of the patients with PAH were significantly improved（P〈0.05）while hepatic function （AST,ALT,TBIL） did not show obvious difference（P〉0.05）. Conclusion.Ambrisentan is effective and safe in the clinical treatment of PAH by reducing mPAP and PVR, improving cardiac function and increasing 6MWD.